Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

AMBER: Azithromycin to Modify Bronchiectasis Exacerbation Risk - A Double-Blind Placebo-Controlled Randomized Trial in Adults With Non-Cystic Fibrosis Bronchiectasis

NCT07608328 is registered in ClinicalTrials.gov with Assiut University as lead sponsor.

NCT NCT07608328
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07608328 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
AMBER: Azithromycin to Modify Bronchiectasis Exacerbation Risk - A Double-Blind Placebo-Controlled Randomized Trial in Adults With Non-Cystic Fibrosis Bronchiectasis
Lead sponsor
Assiut University
Phase
Phase 4
Overall status
Recruiting
Start date
June 29, 2026
Completion date
June 30, 2027
Enrollment
500 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

bronchiectasis, bronchiectasis adult, bronchiectasis with acute exacerbation, non-cystic fibrosis bronchiectasis